JP2018529760A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529760A5
JP2018529760A5 JP2018527836A JP2018527836A JP2018529760A5 JP 2018529760 A5 JP2018529760 A5 JP 2018529760A5 JP 2018527836 A JP2018527836 A JP 2018527836A JP 2018527836 A JP2018527836 A JP 2018527836A JP 2018529760 A5 JP2018529760 A5 JP 2018529760A5
Authority
JP
Japan
Prior art keywords
fviii
coagulation factor
modified
protein
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
JP2018527836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529760A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/046264 external-priority patent/WO2017027545A1/en
Publication of JP2018529760A publication Critical patent/JP2018529760A/ja
Publication of JP2018529760A5 publication Critical patent/JP2018529760A5/ja
Revoked legal-status Critical Current

Links

JP2018527836A 2015-08-12 2016-08-10 長半減期凝固複合体と関連する方法及び組成物 Revoked JP2018529760A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562203973P 2015-08-12 2015-08-12
US62/203,973 2015-08-12
PCT/US2016/046264 WO2017027545A1 (en) 2015-08-12 2016-08-10 Methods and compositions related to long half-life coagulation complexes

Publications (2)

Publication Number Publication Date
JP2018529760A JP2018529760A (ja) 2018-10-11
JP2018529760A5 true JP2018529760A5 (enExample) 2020-12-03

Family

ID=57983769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018527836A Revoked JP2018529760A (ja) 2015-08-12 2016-08-10 長半減期凝固複合体と関連する方法及び組成物

Country Status (10)

Country Link
US (2) US10596232B2 (enExample)
EP (1) EP3334452A4 (enExample)
JP (1) JP2018529760A (enExample)
KR (1) KR20180031775A (enExample)
CN (1) CN107921103A (enExample)
AU (1) AU2016304842A1 (enExample)
BR (1) BR112018002838A2 (enExample)
CA (1) CA2994971A1 (enExample)
IL (1) IL257406A (enExample)
WO (1) WO2017027545A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061281A1 (en) * 2018-09-19 2020-03-26 Cell Machines, Inc. Methods and compositions related to improved factor viii long half-life coagulation complexes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0921817B1 (en) 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylation process
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
US20110040073A1 (en) 2006-04-07 2011-02-17 Novo Nordisk Healthcare A/G Covalent Factor VII-Tissue Factor Complex
EP3231440A1 (en) 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
CA2770609A1 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9234192B2 (en) * 2010-02-16 2016-01-12 Novo Nordisk A/S Conjugated proteins
EP2536754A1 (en) 2010-02-16 2012-12-26 Novo Nordisk A/S Factor viii fusion protein
ES2800983T3 (es) * 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
EA035323B1 (ru) * 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
DK2796145T3 (da) * 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
FR3007860A1 (fr) * 2013-06-27 2015-01-02 France Telecom Procede d'interaction entre un objet numerique, representatif d'au moins un objet reel ou virtuel localise dans un perimetre geographique distant, et un dispositif de pointage local
WO2014210547A1 (en) 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker

Similar Documents

Publication Publication Date Title
EP3243833B1 (en) Site-directed modification of fviii
KR20110017420A (ko) 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인
US20200289624A1 (en) Methods and compositions related to long half-life coagulation complexes
JP2018529760A5 (enExample)
US20220118063A1 (en) Methods and compositions related to improved factor viii long half-life coagulation complexes
AU2016203693B2 (en) Site-directed modification of FVIII